PWA
CRNX icon

Physician Wealth Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Physician Wealth Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15
Closed -$699 – 2098
2025
Q4 		$699 Sell
15
-7
-32% -$312 ﹤0.01% 1738
2025
Q3 		$917 Buy
+22
New +$703 ﹤0.01% 1632

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Physician Wealth Advisors's CRNX Position: Q1 2026 in Review

Physician Wealth Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 15 shares — an estimated $699 sold.

Physician Wealth Advisors first reported a position in CRNX in Q3 2025 and held it in 2 quarters. The position peaked at $917 in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Physician Wealth Advisors reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Physician Wealth Advisors sold 15 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $699.
  • Physician Wealth Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Physician Wealth Advisors's Crinetics Pharmaceuticals position peaked at $917 in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Physician Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.